Shots:
Janux has entered into a collaboration & exclusive global license agreement with BMS to develop a novel, undisclosed tumor-activated therapy targeting a validated solid-tumor antigen expressed across multiple cancer types
Janux will advance the program through preclinical development & IND submission, after which BMS will hold the IND, lead global development & commercialization, with…
